Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 34.12 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Exelixis Inc < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > 3 Magnificent Stocks Under $100 to Buy in November November 03, 2024 The price could be right for these stocks. Via The Motley Fool Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? November 03, 2024 The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts. Via Benzinga Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday October 30, 2024 Via Benzinga Exelixis (EXEL) Q3 2024 Earnings Call Transcript October 30, 2024 EXEL earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Earnings Preview: Exelixis October 28, 2024 Via Benzinga 1 No-Brainer Stock to Buy With $40 October 23, 2024 The midcap biotech just became an even better buy. Via The Motley Fool Analyst Ratings For Exelixis October 21, 2024 Via Benzinga Navigating 16 Analyst Ratings For Exelixis October 21, 2024 Via Benzinga Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update October 29, 2024 From Exelixis, Inc. Via Business Wire Biotech Momentum Trades For The Q4 Rally October 29, 2024 The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. Via Talk Markets Momentum Has Narrowed Again, Significantly October 28, 2024 It is more of a stock pickers market than usual as momentum factors are currently exaggerated. Via Talk Markets In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. October 18, 2024 In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals. Via Chartmill Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 October 15, 2024 From Exelixis, Inc. Via Business Wire Key Takeaways From Exelixis Analyst Ratings October 04, 2024 Via Benzinga A Closer Look at 5 Analyst Recommendations For Exelixis September 18, 2024 Via Benzinga Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories October 15, 2024 From Exelixis, Inc. Via Business Wire Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma October 14, 2024 From Exelixis, Inc. Via Business Wire Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas October 13, 2024 It is Fall clean up time. Sell lagging and sagging companies. Via Talk Markets NASDAQ:EXEL, an undervalued stock with good fundamentals. August 15, 2024 Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag. Via Chartmill Expert Outlook: Exelixis Through The Eyes Of 5 Analysts August 08, 2024 Via Benzinga NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. September 27, 2024 For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. Via Chartmill 2 Growth Stocks to Buy With Less Than $100 September 26, 2024 No need to break the bank to get in on these likely long-term winners. Via The Motley Fool Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine September 16, 2024 From Exelixis, Inc. Via Business Wire Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 September 15, 2024 From Exelixis, Inc. Via Business Wire In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. September 06, 2024 EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. Via Chartmill Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September August 28, 2024 From Exelixis, Inc. Via Business Wire 3 Stocks to Buy for a Soft Landing, If There Is One August 15, 2024 Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes Via MarketBeat Topics Economy Exposures Economy Interest Rates Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 After Monday's panicked global sell-off, markets have calmed down. Via Investor's Business Daily Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results August 07, 2024 Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance.... Via Benzinga Exposures Product Safety US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' August 07, 2024 Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... Via Benzinga Topics Stocks Exposures US Equities < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
